SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The SPY is facing significant downward pressure as market sentiment sours following a geopolitical address that failed to calm fears regarding the ongoing conflict in Iran and rising oil prices. Investors are expressing frustration with volatile trading, fueled by skepticism over leadership's economic strategy and concerns that inflation and supply chain disruptions will persist through the upcoming holiday weekend.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The QQQ is facing heightened volatility as market participants react to the President's latest remarks, which failed to signal a clear end to Middle East tensions and instead hinted at a prolonged conflict. The community is actively debating the implications of potential supply chain disruptions, particularly in the energy sector, leading many to hedge against further downside risk before the upcoming holiday weekend.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund is experiencing extreme volatility as market participants weigh conflicting signals between President Trumps claims of an imminent exit from the Iran conflict and reports of continued military escalation, including attacks on energy infrastructure. Community sentiment remains polarized, with many traders anticipating that supply risks in the Strait of Hormuz will sustain higher oil prices despite official rhetoric aimed at de-escalation.

“This Is Fine” is unique as a meme for two reasons. One, while sometimes modified, it’s most commonly used in an unaltered state. Second, it’s still popular and used, despite now being nearly nine years old. $Fine is a both a meme and culture coin, meaning it is heavily focused on the use of memes and community engagement.  You can get involved with $Fine by purchasing tokens on Uniswap, participating in community discussions on Telegram, Twitter or medium, and spreading the word about $Fine through memes. You can sell your $fine tokens on Uniswap, but the project encourages holding onto them and participating in the community to drive the price up.  Longevity and Unaltered State:  One of the distinctive aspects of the $Fine token is its association with the "This Is Fine" meme. Unlike other memes that often undergo modifications or alterations over time, the $Fine meme is primarily used in its original, unaltered state. This contributes to its enduring popularity and recognition. Enduring Popularity:  Remarkably, despite being almost a decade old, the "This Is Fine" meme remains popular and widely used. This enduring popularity serves as a testament to its cultural significance and the impact it has had on internet culture. Meme and Culture Coin:  $Fine transcends the traditional notion of a cryptocurrency and is categorized as a "meme and culture coin." This designation indicates a strong emphasis on leveraging memes and fostering community engagement as integral components of the project's identity and development.

Refinable

Investors are fueling intense discussion around Refinable ($FINE) by highlighting its potential as an early-stage meme coin project tied to influential developer connections. Community members are actively sharing their experiences with low market-cap entry points and viral growth potential, while simultaneously expressing frustration over technical discrepancies with the ticker's chart and pricing on the platform.

Applied Digital Corporation

Applied Digital is currently at the center of high-conviction community debate as investors weigh strong AI data center tailwinds against intense geopolitical volatility and concerns over impending hyperscaler lease deadlines. While bulls are aggressively buying the dip and highlighting an investment-grade credit upgrade for the Polaris Forge facilities, others are expressing anxiety over potential macroeconomic headwinds and the stock's sensitivity to regional conflicts.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the focal point of intense market sentiment as investors weigh volatile geopolitical headlines against high-stakes upcoming Q1 production and delivery figures. While retail and institutional traders debate the stock's future amid shifting AI narratives and potential SpaceX IPO catalysts, the community remains sharply divided between those positioning for a delivery beat and skeptics questioning long-term growth fundamentals.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is experiencing intense volatility and speculative trading as market participants react to a high-stakes address regarding the ongoing military situation in Iran. Community discussion is sharply divided, with intense debate centering on the potential economic fallout of prolonged geopolitical conflict and widespread skepticism regarding the company's long-term fundamental value.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently trending as investors debate the impact of AI infrastructure demand, semiconductor supply chain constraints, and broader market volatility. The community remains sharply divided, with bulls pointing to long-term growth in data center performance and AI-driven compute requirements, while bears focus on recent technical breakdowns, geopolitical risks, and high valuation concerns.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently a primary market engine, acting as a structural anchor for the AI-driven resurgence in the semiconductor sector. Community discussion is heavily focused on whether this compute dominance can sustain its current trajectory amidst ongoing geopolitical volatility and high institutional capital concentration.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is trending as investors digest a major $252 million settlement with the U.S. Commerce Department, removing a significant regulatory overhang while the company prepares to report quarterly earnings. The stock remains a focal point for the semiconductor community as participants weigh ongoing AI-driven infrastructure demand against geopolitical risks and export limitations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Guardian Pharmacy (GRDN) Soars 9.1%: Is Further Upside Left in the Stock?

Guardian Pharmacy (GRDN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Nordea Investment Management AB Takes Position in Akebia Therapeutics, Inc. $AKBA

Nordea Investment Management AB acquired a new position in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 752,106 shares of the biopharmaceutical comp...

Is the Options Market Predicting a Spike in Akebia Therapeutics Stock?

Investors need to pay close attention to AKBA stock based on the movements in the options market lately. 

Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference

Akebia Therapeutics (NASDAQ:AKBA) executives outlined the company's near- and mid-term priorities at the Leerink Partners Global Healthcare Conference, emphasizing the commercialization of its anemia...

Akebia Therapeutics (NASDAQ:AKBA) CEO John Butler Purchases 69,270 Shares

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) CEO John Butler purchased 69,270 shares of the business's stock in a transaction on Wednesday, March 4th. The stock was acquired at an...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the target of a large decline in short interest in February. As of February 13th, there was short interest totaling 31,207,330 shares, a...

Citigroup Inc. Has $5.23 Million Position in Akebia Therapeutics, Inc. $AKBA

Citigroup Inc. boosted its stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 1,324.7% in the third quarter, according to its most recent Form 13F filing with the Securities and...

Wall Street Zen Downgrades Akebia Therapeutics (NASDAQ:AKBA) to Hold

Wall Street Zen cut shares of Akebia Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday...

Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results, Misses Expectations By $0.02 EPS

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts...

<ul class="summary-bullets"><li>Enrollment is also underway for the company’s study of its other experimental therapy praliciguat in focal segmental glomerulosclerosis (FSGS).</li><li>In 2026, the company expects a significant revenue growth for Vafseo through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.</li><li>The company ended Q4 with cash and cash equivalents of about $184.8 million, which it expects to be sufficient to fund current operating plan for at least two years.</li></ul>&nbsp;Shares of Akebia Therapeutics Inc (AKBA) rose 7% on Thursday after the company announced that it expects significant revenue growth for its approved anemia medicine Vafseo in 2026 while it also advances its clinical pipeline.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-reports-fourth-quarter-and-full-year-2025">said</a> on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027. Akebia acquired the experimental drug from Q32 Bio in November. The company will explore the drug in IgA nephropathy, lupus nephritis and C3 glomerulopathy, it said.Enrollment is also underway for the company’s study of its other experimental therapy praliciguat in focal segmental glomerulosclerosis (FSGS). Target enrollment for the trial is approximately 60 patients.<h2 class="st-heading-2">Future Of FDA-Approved Medicines</h2>Akebia has two medicines approved by the U.S. Food and Drug Administration including <a href="https://stocktwits.com/news-articles/markets/equity/akebia-therapeutics-stock-slumps-after-fda-meeting-ends-without-path-forward-for-vafseo-label-expansion/cLGZtPhR3wx">Vafseo </a>for the treatment of anemia due to chronic kidney disease (CKD) in dialysis patients. In 2026, the company expects a significant revenue growth for Vafseo through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.“Vafseo commercial trends are showing marked improvement in early 2026... Patient access to Vafseo therapy now stands at 290,000 patients, and early data points to improved patient adherence rates, which we believe are enhanced as a result of dialysis organizations deciding to implement observed dosing protocols. These dynamics, along with the building evidence of clinical differentiation, are expected to drive significant Vafseo revenue growth in 2026 and beyond…, ” said CEO John P. Butler.<h2 class="st-heading-2">Q4 Numbers</h2>For the fourth quarter, the company reported net product revenues of $54.3 million, owing to a quarter-on-quarter increase in prescribers for Vafseo which was launched in the U.S. in Jan. 2025 and an increase in sales volume for Auryxia. Analysts on average were expecting the company to report revenue of $46.09 million.Net loss per share for the period came in at $0.05, compared to a loss of $0.10 in the corresponding quarter of 2024, but above an analyst estimate of a loss of $0.04.The company ended the quarter with cash and cash equivalents of about $184.8 million, which it expects to be sufficient to fund current operating plan for at least two years.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AKBA stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user highlighted the several potential catalysts for the stock including accelerating adoption for Vafseo and cash hoard.<stembedurl>https://www.stocktwits.com/ROCKET123/message/645988666</stembedurl>Another voiced hopes for stock as much as doubling “sooner or later.”<stembedurl>https://www.stocktwits.com/Andi77/message/645980832</stembedurl><a href="https://stocktwits.com/symbol/AKBA">AKBA stock</a> has fallen 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvda-stock-falls-michael-burry-says-nvidia-purchase-commitments-akin-to-cisco-dot-com-bubble/cZTGi6FRIRb">Michael Burry Warns Nvidia’s ‘Purchase Commitments’ Akin To Cisco At The Top Of Dot-Com Bubble — NVDA Stock Falls 5%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Akebia Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.

Equity

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.


Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Akebia Therapeutics Inc.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

AKBA
Akebia Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AKBA News

AKBAAkebia Therapeutics Inc.